Why the study?
Does intravenous phentolamine improve clinical outcomes and cardiac biomarkers in children with severe hand, foot and mouth disease combined with pulmonary edema?
Population
105 children with severe hand, foot and mouth disease (HFMD) combined with pulmonary edema (PE)
Comparison
Phentolamine intravenously at a loading dose of… vs No phentolamine infusion
Design
Cohort
Authors
Loading...
Phentolamine may lower cardiac markers, ventilation time and mortality in severe HFMD with PE; leaves open need for randomized trials before practice change.
Does intravenous phentolamine improve clinical outcomes and cardiac biomarkers in children with severe hand, foot and mouth disease combined with pulmonary edema?
Intravenous phentolamine may reduce mortality, shorten hospitalization, and improve cardiac biomarkers in children with severe HFMD complicated by pulmonary edema.
Yan et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: